Primary cell culture derived from malignant pleural effusion for personalized medicine
Keywords:
Pleural effustion, Primary cell culture, Cancer, Drug responseAbstract
Objective : To determine the sensitivity to anticancer drug in a model of primary cell culture obtained from MPE.
Method : The MPEs of cancer patients were obtained by thoracentesis at the National Cancer Institute of Thailand between January and June 2022. Cytology test was used to diagnosed cancer. Cells were cultured in DMEM media supplemented with 20% fetal bovine serum in 6-cm cell culture plates. Ex vivo sensitivity to anti-cancer drugs was analyzed using MTT assay.
Result : 8 MPEs from 2 lung cancer patients and 6 breast cancer patients were collected in this study (Volume 3-40 mL). Five patients (62.5%) had positive cytology whereas three patients (37.5%) had negative cytology. Interestingly, primary cell culture was successfully established from 5 out of 5 patients with positive cytology. The degree of sensitivity to cisplatin varied from person to person. 1 patient was classified as good responders whereas 1 patient had no response to this drug.
Conclusion : The established primary cell culture from pleural effusion could serve as a valuable tool for drug screening and drug development.
References
Esparza-Lopez J, Martinez-Aguilar JF, Ibarra-Sanchez MJ. Deriving Primary Cancer Cell Cultures for Personalized Therapy. Rev Invest Clin. 2019;71(6):369-80.
Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, et al. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Rep. 2017;21(11):3298-309.
Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3-5.
Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3-4):79-100.
Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers (Basel). 2021;13(9): 1-22.
Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 2017;8(3):3933-45.
Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi M, et al. The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. Int J Mol Sci. 2017;18(7):1-30.
Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2019;116(21):377-86.
Kulandaisamy PC, Kulandaisamy S, Kramer D, McGrath C. Malignant Pleural Effusions-A Review of Current Guidelines and Practices. J Clin Med. 2021;10(23):1-7.
Rodriguez-Panadero F, Janssen JP, Astoul P. Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J. 2006;28(2):409-22.
Basak SK, Veena MS, Oh S, Huang G, Srivatsan E, Huang M, et al. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One. 2009;4(6):1-12.
Hillerdal CO, Otvos R, Szatmari T, Own SA, Hillerdal G, Dackland AL, et al. Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions. Oncotarget. 2017;8(47):82885-96.
Xu Y, Zhang F, Pan X, Wang G, Zhu L, Zhang J, et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. Cancer Commun (Lond). 2018;38(1):1-12.
Seo HY, Kim SC, Roh WL, Shin YK, Kim S, Kim DW, et al. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types. Sci Rep. 2022;12(1):1-30.
Cutler DM. Early Returns From the Era of Precision Medicine. JAMA. 2020;323(2):109-10.
Chantharakhit C, Sujaritvanichpong N. Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score. Asian Pac J Cancer Prev. 2022;23(1):25-31.
Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, et al. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med. 2016;14(61):1-14.
Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005;23(22):5117-25.
Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001;234(2):215-23.
Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mahasarakham Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
วารสารนี้เป็นลิขสิทธิ์ของโรงพยาบาลมหาสารคาม
